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ORIGINAL ARTICLE

Formation of Osteochondral Organoids from Murine Induced Pluripotent Stem
Cells
Shannon K. O'Connor, MD, PhD 1,2,3,*, Dakota B. Katz, BS 1,2,4,5,*, Sara J. Oswald, MS 1,2,5, Logan Groneck,
BS 1,2,4, and Farshid Guilak, PhD 1,2,4,5

Osteoarthritis is a debilitating joint disease that is characterized by pathologic changes in both cartilage and
bone, potentially involving cross talk between these tissues that is complicated by extraneous factors that are
difficult to study in vivo. To create a model system of these cartilage–bone interactions, we developed an
osteochondral organoid from murine induced pluripotent stem cells (iPSCs). Using this approach, we grew
organoids from a single cell type through time-dependent sequential exposure of growth factors, namely
transforming growth factor β-3 and bone morphogenic protein 2, to mirror bone development through
endochondral ossification. The result is a cartilaginous region and a calcified bony region comprising an
organoid with the potential for joint disease drug screening and investigation of genetic risk in a patient or
disease-specific manner. Furthermore, we also investigated the possibility of the differentiated cells within
the organoid to revert to a pluripotent state. It was found that while the cells themselves maintain the
capacity for reinduction of pluripotency, encapsulation in the newly formed 3D matrix prevents this process
from occurring, which could have implications for future clinical use of iPSCs.
Impact statement
The regeneration of integrated articular cartilage and bone tissues from a single cell source has been a
challenge in the field of osteochondral tissue engineering and osteoarthritis disease modeling. The goal of
this study was to develop an osteochondral organoid system using a single murine induced pluripotent stem
cell (iPSC) source in a scaffold-free system and to determine whether differentiated iPSCs retain the
potential to undergo reinduction of pluripotency. Our findings indicate that sequential differentiation into
chondrogenic and osteogenic lineages can be used to develop osteochondral organoids, and encapsulation
within a cartilaginous matrix prevents the reinduction of pluripotency in differentiated iPSCs.
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Introduction

O

steoarthritis (OA) is a whole joint disease characterized by the degradation of articular
cartilage with changes also occurring in the subchondral bone, including osteophyte formation and
increased bone remodeling.1–3 In vitro systems consisting of chondrocytes or tissue explants provide
important model systems for studying cartilage biology and often serve as the initial basis for screening of
disease-modifying OA drugs (DMOADs). However, the joint is increasingly viewed as a complex organ,
with diseases impacting multiple tissues on many levels. To focus on the cross talk between cartilage and
bone, the development of a model system that consists of these two tissues could provide additional insight
into osteochondral biology and drug development.2,4–6 In this regard, “organoids” are an emerging field that
could present a platform for studying interactions of multiple tissues in vitro, as well as being a model for
testing of DMOADs.7–10
Several tissue engineering approaches have been developed for the creation of an osteochondral
construct that is designed for implantation as a means of replacing or repairing injured or diseased tissues in
the joint.7,11 The strategies used for creating these constructs generally rely on the use of a variety of cell
sources, scaffold materials, or geometries to create a bilayer or gradient from cartilage to bone or bioreactors
to spatially deliver different media and growth factors to create the different tissues.7,11–14 Instead, as a
construct design strategy, bone development can be taken into consideration: long bones are formed when
cartilage anlagen are subsequently converted to bone through endochondral ossification.15 The cells that
contribute to this osseous tissue formation may be either osteogenic cells that replace the hypertrophic
chondrogenic cells or chondrocyte-like cells that transdifferentiate directly to osteogenic cells.16–18 Indeed,
several tissue engineering approaches have attempted to enhance osteogenesis of mesenchymal stem cells
(MSCs) by differentiating them through an initial chondrogenic precursor phase.19,20
Induced pluripotent stem cells (iPSCs) provide a highly expandable and genetically-defined source of
pluripotent cells for organoid tissue engineering: they exhibit pluripotency, allowing for multiple tissue
types to be differentiated from a single cell source.21 In addition, iPSCs are a powerful tool for investigation
of genetic diseases, as they can be reprogrammed from the tissue of a patient with that disease22 or
genetically modified using genome-editing methods to develop disease-specific organoid models.23
Subsequently, drug screening can be accomplished in a patient or disease-specific manner.24
In osteochondral tissue engineering, previous work has determined differentiation protocols of murine
iPSCs (miPSCs) to both chondrogenic and osteogenic lineages individually, utilizing transforming growth
factor β (TGF-β) and bone morphogenic protein 2 (BMP2) to drive the specific differentiation.25,26
Additional previous work has demonstrated bone-like and cartilage-like composites from miPSCs.27
However, recapitulation of endochondral ossification in miPSCs to create an osteochondral organoid has not
previously been done. By synthesis of these separate differentiation protocols, iPSCs enable investigation
not only of the endochondral ossification pathway but also the potential for transdifferentiation of
chondrocytes in the development of osseous tissue.
This study demonstrates a time-dependent method for the creation of tissue-engineered osteochondral
organoids for use in osteochondral research as a step toward future clinical applications. To create an
osteochondral organoid, we differentiated iPSCs down a chondrogenic lineage using TGF-β3 and
subsequently induced osseous tissue formation by utilizing BMP2. We characterized this osteochondral
organoid to verify both chondrogenesis and osteogenesis. We also examined the hypothesis that re-exposure
of the cells to the Yamanaka factors used to initially induce pluripotency in the mouse tail fibroblast (Oct4,
Sox2, Klf4, and cMyc) would revert the cells back to a pluripotent state following terminal chondrogenic
differentiation.28 This would allow for subsequent differentiation to a different cell lineage.
The iPSCs used in this study were initially induced using a doxycycline-inducible lentiviral vector for
the pluripotency factors. Therefore, it was hypothesized that adding doxycycline to the culture media would
reactivate this vector and result in expression of the Yamanaka factors. This approach would allow us to test

whether reinduction of pluripotency in chondrogenically-differentiated cells would facilitate the sequential
induction of osteogenesis, in comparison to osteogenic induction through direct transdifferentiation of the
chondrocyte-like cells to osteogenic cells. In addition, further elucidation of the functionality of the
doxycycline-inducible vector on terminally-differentiated cells is vital for the safety of future iPSC-derived
engineered constructs for clinical applications.29–31
Method
Prechondrogenic differentiation and sorting of miPSCs

The timeline for experimental methods is shown in Figure 1. miPSCs were induced, cultured, and sorted
for chondrogenic potential as previously described.25 Briefly, a previously-derived iPSC line was created
from mouse tail fibroblasts that were transduced with a doxycycline-inducible lentiviral vector for the
expression of Sox2, Oct4 (pou5f1), Klf4, and c-Myc and cultured in iPSC media containing dulbecco's
modified eagle's medium - high glucose (DMEM-HG) (Gibco), 20% lot-selected fetal bovine serum (FBS;
Atlanta Biologicals), MEM nonessential amino acids (NEAA; Gibco), β-mercaptoethanol (Gibco),
gentamicin (Gibco), and mouse leukemia inhibitory factor (LIF; Millipore ESGRO). miPSCs were
nucleofected with a linearized pCOL2-EGFP-SV40-NEO reporter plasmid (kindly provided by Dr. William
Horton, Shriners Hospitals for Children - Portland).32 Cells were then expanded between days 2 and 12
posttransfection with G418 (200 μg/mL; Invitrogen) as previously described.25 G418-resistant clones were
individually expanded and differentiated in micromass culture in chondrogenic media containing DMEMHG (Gibco), NEAA (Gibco), β-mercaptoethanol (Gibco), ITS+ (BD), penicillin–streptomycin (Gibco), 50
μg/mL L-ascorbic acid 2-phosphate (Sigma), and 40 μg/mL L-proline (Sigma). Micromasses were treated
with 50 ng/mL mBMP-4 (R&D Systems) and 100 nM dexamethasone on days 3–5 of culture.

FIG. 1. Timelines for organoid formation and pluripotency testing. Data collection points shown for miPSCs (green), pellets in
chondrogenesis (blue), and samples with or without doxycycline (dox) treatment (yellow/red). iPSC, induced pluripotent stem
cell; miPSC, murine iPSC. Color images are available online.

Post micromass culture, the micromasses were digested for 1 h at 37°C using 0.4% collagenase type II
(Worthington), 1320 PKU/mL pronase (Calbiochem), and 10 μg/mL DNase I (Worthington) and pipetted
every 15 min during incubation. Cells were centrifuged, incubated with 0.25% trypsinethylenediaminetetraacetic acid (EDTA) for 5 min, and resuspended in sort medium containing DMEM-HG,
2% FBS, DNase I, 10 mM Hepes (Gibco), 2 × penicillin-streptomycin-fungizone, and 5 μM propidium

iodide (BioLegend). Cells were sorted based on GFP expression using the 100 μM nozzle of an Aria II flow
sorter (BD BioSciences). Approximately 10–20% of cells were GFP+ and therefore collagen II positive.
Pellet culture for chondrogenesis, osteogenesis, and pluripotency reinduction

After sorting, cells were expanded on gelatin-coated plates at 1 × 104 cells/cm2 in chondrogenic
differentiation media with 4 ng/mL human basic fibroblast growth factor (hbFGF) (Roche) and 10% FBS.
Cells were passaged every 3 days for two passages using 0.05% trypsin-EDTA for 5 min. After the second
passage, cells were resuspended in chondrogenic media with 10 ng/mL TGF-β3 and pelleted by
centrifugation at 2.5 × 105 cells/pellet, 200 g for 5 min in 15 mL conical tubes.
Pellets were cultured in chondrogenic media for 29 days, with media changes every 3 days. For
osteochondral organoids, pellets continued to be cultured with 10 ng/mL TGF-β3 in chondrogenic media for
16 additional days with or without the addition of 10 μg/mL doxycycline (Sigma) followed by 28 days in
osteogenic media containing 12.5 ng/mL BMP2 (RnD), 10% FBS, DMEM-HG (Gibco), NEAA (Gibco), βmercaptoethanol (Gibco), penicillin-streptomycin (Gibco), 50 μg/mL L-ascorbic acid 2-phosphate (Sigma),
dexamethasone, and 10 mM β-glycerophosphate (Sigma).
Mycoplasma testing was performed regularly by a core facility at Washington University. Additional
DAPI staining further demonstrated negative mycoplasma results.
Gene expression by qRT-PCR

Pellets were homogenized in lysis buffer in a bead beater. RNA isolation was performed according to
manufacturer's instructions (Total RNA Purification Plus Micro Kit, Norgen). cDNA synthesis was
performed using SuperScript IV First-Strand Synthesis System (Thermo Fisher), in parallel with a No
Template Control (NTC). PCR was performed with TaqMan Gene Expression Assay probes (Thermo
Fisher) (Table 1) and TaqMan Fast Advanced Master Mix. Data analysis was performed with the ΔΔCT
method. GAPDH was used as the endogenous control gene. All samples were compared to miPSCs.
Table 1. Quantitative Polymerase Chain Reaction Primer Probes (Table view)

Gene
Acan
Alpl
Bglap
Col1a2
Col2a1
Col10a1
Gapdh
Hprt
Ibsp
Nanog
Oct4/Pou5F1
Prg4
Runx2
Sox2
Sox9
Sp7

Name
Aggrecan
Alkaline phosphatase
Osteocalcin
Type I collagen
Type II collagen
Type 10 collagen
Glyceraldehyde 3-phosphate dehydrogenase
hypoxanthine guanine phosphoribosyl transferase
Bone sialoprotein
Nanog homeobox
Octamer-binding transcription factor 4
Lubricin
Runt-related transcription factor 2
sex determining region Y-box 2
sex determining region Y-box 9
Osterix

Probe
Mm00545794_m1
Mm00475834_m1
Mm03413826_mH
Mm00483888_m1
Mm01309565_m1
Mm00487041_m1
Mm99999915_g1
Mm00446968_m1
Mm00492555_m1
Mm01617762_g1
Mm03053917_g1
Mm01284582_m1
Mm00501584_m1
Mm03053810_s1
Mm00448840_m1
Mm04209856_m1

Histology and immunohistochemistry

Pellets were fixed in 10% Neutral Buffered Formalin for 16 h and dehydrated, paraffin embedded, and
sectioned at 8 μm thickness. Safranin-O/fast green/hematoxylin staining was performed under standard
protocols using osteochondral sections from mouse knee joints as controls. Von Kossa staining was

performed according to manufacturer's instructions (Abcam), with a knee joint dissected from an 11-day-old
mouse as control.
For immunohistochemistry, sections were treated with xylene and ethanol in decreasing concentrations.
For type II collagen (Iowa II-II6B3, 1:1 in 10% goat serum), type VI collagen (Fitzgerald 70R-CR009 × ,
1:1000 in 1% BSA), and type X collagen (Sigma c7974, 1:400), epitope retrieval was performed with
Digest-All 3 Pepsin (Invitrogen) at room temperature for 5 min, treated with a methanol-peroxidase solution,
blocked for 30 min (goat serum for type X collagen, goat serum with the addition of cold fish gelatin for
type II collagen, and for type VI collagen, 2% goat serum, 1% BSA, 0.1% Triton X-100, 0.05% Tween 20,
0.01 M PBS (pH 7.2)), then incubated for an hour at room temperature in primary antibody. Secondary
antibody incubation was performed for 30 min at room temperature (ab97021 for type II collagen and type
X collagen and ab6720 for type VI collagen, 1:500), followed by HRP Streptavidin treatment and AEC Red
Single (Histostain Plus; Invitrogen), counterstained with hematoxylin, and mounted with VectaMount
(Vector Labs). For type I collagen (8D4A1, Chondrex, 1:200, biotinylated), epitope retrieval was performed
with proteinase K diluted in TE buffer and incubated at 37°C for 20 min, then treated with methanolperoxidase solution, and blocked for 30 min (goat serum) before primary incubation. Type I collagen slides
were not counterstained. Osteochondral sections from mouse knee joints were used as controls. Final
histology images were taken on a VS120 microscope imaging system (Olympus) at 20 × magnification, with
consistent brightfield settings for each stain.
MicroCT analysis

Pellets were serially dehydrated to 70% ethanol for microCT imaging (SkyScan1176; Bruker) at 40 kV
and 600 μA with no filter at a resolution of 8.75 μm. Images were reconstructed at dynamic range 0 to 0.16,
beam hardening 20, ring artifact correction 10. Total pellet tissue volume (TV), calcified bone volume (BV),
and bone mineral density (BMD) values were calculated based on comparison to hydroxyapatite phantoms
using CTAnalyser software (Bruker). Images were generated in CTVox software (Bruker).
Biochemical analysis

Pellets were digested in papain at 65°C for 16 h. dsDNA was measured with PicoGreen dsDNA
Quantitation Kit (Invitrogen), sulfated glycosaminoglycans (s-GAGs) were measured with the DMMB
assay, and total collagen was measured with the hydroxyproline assay. To quantify calcium content, pellets
were decalcified by incubating in 5% formic acid for 30 min. Calcium concentration was measured using the
Calcium Colorimetric Assay Kit (Fisher).
Pluripotency testing

To test pluripotent potential, pellets were cultured up to day 29 as described above and then divided into
two groups (Fig. 1). One group of pellets was cultured for 16 days in iPSC media containing 20% FBS,
DMEM-HG (Gibco), NEAA (Gibco), β-mercaptoethanol (Gibco), gentamicin (Gibco), and mouse LIF
(EMD Millipore), with 10 μg/mL doxycycline. The other group of pellets was dissociated using 0.4%
collagenase type II (Worthington), 1320 PKU/mL pronase (Calbiochem), and 10 μg/mL DNase I
(Worthington) and plated in monolayer on laminin-coated (Sigma L2020) plates in iPSC media with 10
μg/mL doxycycline, 1 μM PD0325901 (Cayman Chemical), and 3 μM CHIR99021 (Cayman Chemical) for
feeder-free culture utilizing the 2i system for 16 days. The 2i-laminin system is used in place of using a
feeder layer of cells to support pluripotency. It has been well established in the stem cell literature that this
system does not induce pluripotency, but rather helps prevent differentiation in pluripotent cells. The
maintenance of pluripotency by the laminin-2i system has been shown to last for eight passages.33–35 After
16 days, the remaining pellets were also dissociated and plated in monolayer. Both monolayer iPSC groups

were passaged seven additional times in iPSC media without doxycycline before staining for pluripotency
markers.33
For imaging, 5 × 104 cells were plated into each well of a four-well chambered culture slide
(Falcon/Corning) precoated with laminin. After culturing for 5 days, wells were rinsed 3 × in phosphatebuffered saline (PBS), fixed in 4% paraformaldehyde in PBS with 0.1% Tween for 20 min at room
temperature, rinsed 3 × in PBS, permeabilized for 20 min at room temperature in 0.1% Triton X-100 in PBS,
rinsed 4 × in PBS with 0.1% Triton-X, and incubated in Blocking Buffer (10% FCS in PBS) for 40 min at
room temperature. Primary antibodies were incubated overnight at 4°C in precooled Blocking Buffer
(Abcam 1:100 for each: Nanog 80892, Oct4 27985, SSEA-1 16285). Wells were rinsed 4 × in PBS with
0.1% Triton-X. Secondary antibodies were incubated for 75 min at 4°C in the dark in Blocking Buffer (all
Invitrogen, for Nanog, 1:1000 Alexa Fluor Plus 488 (GFP) A-32731, for Oct4, 1:600 Alexa Fluor 568 (RFP)
A-11057, and for SSEA-1, 1:1000, Alexa Fluor 647 (Cy5) A-32728). Wells were rinsed 2 × in PBS with
0.1% Triton-X and mounted in Prolong Gold with DAPI (Invitrogen). Slides were imaged at 10 × and 40 ×
using the Cytation 5 system (Agilent Technologies).
Statistical analysis

Experimental data reported as mean ± SEM were compared using a Student's t-test, a one-way ANOVA
followed by a post hoc Tukey's test, or a two-way ANOVA. Data were analyzed with JMP statistical
software with a significance level set to α = 0.05.
Experiment
Chondrogenic outcomes

After 15, 29, and 45 days of chondrogenic culture, expression of chondrogenic genes Acan, Col2a1,
Prg4, and Sox9 was significantly upregulated compared to original miPSCs or day 0 pellets (Fig. 2A).
Chondrogenic gene expression decreased during the osteogenic phase from day 45 through day 73 but
maintained expression levels significantly above miPSC levels. Doxycycline treatment had no statistically
significant effect on gene expression at either day 45 or day 73.

FIG. 2. Organoid chondrogenesis. (A) Gene expression of chondrogenic genes at days 0, 15, 29, 45, and 73 of culture
compared to miPSCs. Reference gene is GAPDH. Data points and error bars demonstrate mean ± SEM. Groups not labeled
with the same letter are significantly different by one-way ANOVA with post hoc Tukey–Kramer analysis with p < 0.05
(nondox groups only). Significance of two-way ANOVA for days 45 and 73 with and without dox denoted by brackets and
asterisks. n = 3 for miPSC control, n = 6–8 for experimental groups. (B) Biochemical analysis of DNA and ECM components
of pellets at days 45 and 73 with and without doxycycline treatment. Data points and error bars demonstrate mean ± SEM.
Significance determined by two-way ANOVA with p < 0.05. Significance denoted by brackets and asterisks. n = 4. (C)
Histologic analysis of pellets at days 45 and 73, with or without doxycycline treatment. Top to bottom: Safranin-O/fast
green/hematoxylin staining, immunohistochemical probing of collagen type II, VI, and X (with mouse joint controls). Scale
bars: 200 μm in pellet samples, 100 μm in mouse tissue controls. ECM, extracellular matrix. Color images are available online.

DNA content in the pellets increased from day 45 to day 73 (Fig. 2B). Doxycycline treatment also
increased DNA content compared to no treatment. Sulfated GAG content decreased after osteogenesis
independent of doxycycline treatment. Total collagen between pre- and postosteogenesis groups was
maintained, independent of doxycycline treatment.
Pellets cultured under chondrogenic conditions showed rich Safranin-O staining throughout the
specimens at 45 days of culture (Fig. 2C). Collagen type II and type VI were confirmed to be present
throughout the pellet by immunohistochemistry (IHC), while collagen type X was minimally present. No
differences were noted between pellets with or without doxycycline treatment. Following osteogenic
induction at day 73, s-GAGs, collagen type II, and collagen type VI were maintained in the pellet
extracellular matrix (ECM) inside the constructs, with new tissue growth on the outside less rich in s-GAGs
and collagen type II. This new tissue growth was rich in type VI collagen. Collagen type X was minimally
present. These chondrogenic ECM components were present independent of treatment with doxycycline.
Osteogenic outcomes

After osteogenic induction, gene expression of Alpl, Bglap, Col1a2, Ibsp, Runx2, and Sp7 were all
significantly increased compared to miPSC levels (Fig. 3A). Col10a1, a hypertrophy gene, was found to be
highest at day 45, the end of the chondrogenic phase, and declined during the osteogenic phase.
Doxycycline treatment had no statistically significant effect on gene expression.

FIG. 3. Organoid osteogenesis. (A) Gene expression of osteogenic and hypertrophic genes at days 0, 15, 29, 45, and 73 of
culture compared to miPSCs. Reference gene is GAPDH. Data points and error bars demonstrate mean ± SEM. Groups not
labeled with the same letter are significantly different by one-way ANOVA with post hoc Tukey–Kramer analysis with p < 0.05
(nondox groups only). Significance of two-way ANOVA for days 45 and 73 with and without dox denoted by brackets and
asterisks. n = 3 for miPSC control, n = 6–8 for experimental groups. (B) Histologic analysis of pellets at day 73 with and
without doxycycline treatment. Top to bottom: Immunohistochemical probing of osteogenic protein collagen type I (with native
mouse tendon control), Von Kossa staining (with nondecalcified young mouse knee control), and Masson's Trichrome staining
(with adult mouse shoulder joint control). Scale bars: 200 μm in pellet samples, 100 μm in mouse tissue controls. (C) MicroCT
images of pellets at day 73 with and without doxycycline treatment. Scale bars: 100 μm. (D) Quantification of MicroCT data
for day 73 pellets with and without doxycycline treatment: BMD, calculated bone volume, total pellet tissue volume, and ratio
of BV/TV. Significance of Student's t-test, p < 0.05, denoted by brackets and asterisks. n = 4. (E) Calcium content of pellet
groups with and without doxycycline treatment at days 45 and 73. Data points and error bars demonstrate mean ± SEM.
Significance of two-way ANOVA, p < 0.05, denoted by brackets and asterisks. n = 4. BMD, bone mineral density; BV/TV, bone
volume to tissue volume. Color images are available online.

Histologic analysis of organoids after a total of 73 days of culture showed osteogenic tissue formation in
the outer region of the organoids, which were rich in collagen and mineralized tissue, as evidenced by IHC
for collagen type I, Von Kossa staining, and Masson's Trichrome staining (Fig. 3B). MicroCT analysis of
organoids at day 73 further confirmed the presence of a dense outer calcified region (Fig. 3C). Quantitative
analysis of microCT images revealed similar BMD, BV, and the ratio of calcified bone volume to total tissue
volume (BV/TV) between pellets with or without doxycycline treatment, although there was an increase in
total TV in the constructs treated with doxycycline (Fig. 3D). A calcium assay of these organoids showed no

calcification after the chondrogenic growth phase at day 45. After osteogenic induction, calcium per pellet
increased to about 35 μg independent of prior doxycycline treatment (Fig. 3E).
Reinduction of pluripotency

To confirm the reactivation potential of the doxycycline-inducible lentiviral vector to express the
Yamanaka factors and induce pluripotency, doxycycline was administered again after chondrogenesis to
cultures either in monolayer or in pellet form. After doxycycline withdrawal, these cultures were maintained
in a 2i-laminin system for seven passages before performing colony pluripotency assays. Cells were treated
with doxycycline in monolayer formed colonies and showed positive staining for alkaline phosphatase,
Nanog, Oct4, and SSEA-1, consistent with a pluripotent phenotype (Fig. 4A). However, cells from pellets
exposed to doxycycline did not form colonies nor demonstrate expression of Nanog, Oct4, or SSEA-1.
Some of these cells did stain positive for alkaline phosphatase, but the morphology of these cells was
inconsistent with pluripotent stem cells.

FIG. 4. Pluripotency outcomes. (A) Colony pluripotency assay. Groups from top to bottom: 40 × images of doxycycline
treatment in monolayer group, 10 × images of doxycycline treatment in monolayer group, 10 × images of doxycycline treatment
in pellet group, 10 × images of no primary antibody control. Positive alkaline phosphatase staining shown in red, with DAPI
overlay in next column. Immunocytochemistry completed with fluorescent probes. Scale bars: 100 μm in 40 × images, 200 μm
in 10 × images. (B) mRNA expression (qRT-PCR) of pluripotency genes at days 0, 15, and 29 of chondrogenic induction, as
well as day 45 after replacing chondrogenic media with iPSC media with doxycycline. Control is initial miPSCs, and reference
gene is GAPDH. Data points and error bars demonstrate mean ± SEM. Groups not labeled with the same letter are significantly
different by one-way ANOVA with post hoc Tukey–Kramer analysis with p < 0.05. n = 3 for miPSC control, n = 6–8 for
experimental groups. Color images are available online.

Gene expression was assessed on days 0, 15, and 29 of chondrogenic culture and on day 45 after 16 days
of doxycycline treatment in iPSC media: all groups demonstrated significantly lower levels of expression of
Alpl, Nanog, Oct4, and Sox2 compared to the miPSCs (Fig. 4B). Alpl, a complicated gene expressed not
only in a pluripotent state but also in multiple other tissue types did increase after doxycycline exposure, but
remained significantly lower than the miPSC group.
Together, these results demonstrate the potential for reactivation of the Yamanaka factors and dedifferentiation to pluripotency in these cells after monolayer induction, but a resistance to de-differentiation
within chondrogenic tissue.
Discussion

We have developed a scaffold and bioreactor-free method of creating osteochondral organoids in vitro
through sequential exposure of iPSCs to chondrogenic and osteogenic growth factors, mimicking the
process of endochondral ossification. Endochondral ossification has been studied for decades but remains
incompletely understood. There are two main theories thought to govern this process: (1) chondrocytes
create an articular cartilage matrix, calcify, die, and are replaced by new cells that migrate in from bone
marrow that become osteocytes to complete the process of bone formation or (2) mature chondrocytes
directly differentiate into osteocytes and osteoblasts to form bone tissue. There are many publications
supporting both theories15–18; our findings support the latter theory, as there is no source of exogenous cells
to repopulate the cartilaginous matrix.
Gene expression, histology, biochemical, and microCT analysis characterized the chondrogenic and
osteogenic aspects of our osteochondral constructs. Given their pluripotent capabilities, as well as the ability
to re-express the Yamanaka factors following differentiation, iPSCs also provide a defined system that
allows us to examine their potential to revert once again to a pluripotent state after differentiation.
Surprisingly, however, we found that chondrogenically differentiated cells within a cartilage pellet did not
revert to a pluripotent state upon reinduction of the doxycycline-inducible pluripotency vector, although this
vector was found to be both functional and capable of inducing pluripotency in cells isolated from pellets
and grown in monolayer.
Previous in vitro osteochondral systems generally have utilized either terminally differentiated adult
osteoblasts and chondrocytes or adult stem cells such as MSCs, to create the different tissue types necessary
for organoid creation.13,36–39 The utility of these terminally differentiated cells is limited by the relatively
low number of cells that are able to be harvested. In addition, to create osteochondral organoids in a patientspecific manner, donor-site morbidity is an unwelcome side effect of cell harvest.40 Furthermore, collection
from diseased joints may further limit in vitro tissue synthesis in this manner. In contrast, iPSCs can be
patient specific, readily expanded in culture while retaining their potential for differentiation, and harvested
from a healthy tissue source.
Throughout 45 days of chondrogenic pellet culture, we found that gene expression for chondrogenic
markers Acan, Col2a1, Prg4, and Sox9 was upregulated over time. These constructs showed a robust
cartilaginous matrix with strong staining for s-GAGs and collagens type II and type VI and little staining for
collagens type I and X. In addition, the cartilaginous matrix, which demonstrated strong staining for s-GAGs
and type II collagen, remained in the center of the organoids even after culture in osteogenic media
containing BMP2, for a total of 73 days in 3D culture. Our results provide further support of the long-term
chondrogenic potential of iPSCs compared to MSCs, which tend to express higher levels of collagen types I
and X and undergo hypertrophy relatively quickly, preventing stable cartilage formation.41–44
In addition, our organoid was created through a timed delivery of growth factors, whereas many previous
MSC-derived osteochondral organoids have been created using different scaffold properties, creating a
complex bioreactor, or by mixing MSCs with already differentiated cells.7,11–13 Instead, we recapitulated
endochondral ossification through a stepwise exposure of growth factors, namely TGF-β3 and BMP2, which
resulted in organoids with a center of cartilaginous tissue and an outer region of bony calcified tissue. A
stepwise strategy for bone formation through endochondral ossification has been previously used with ASCderived chondrogenic pellets that were implanted in vivo.19 Similar to our results, this process resulted in the
formation of a cartilaginous pellet with a calcified outer region. It is interesting that we were able to achieve
this result with only BMP2 instead of all the factors the pellet would have been exposed to in vivo, such as
various matrix metalloproteinases, growth factors, and cytokines. The BMP2 induction of endochondral
ossification aligns with previous research in development, injury repair, and regeneration in which BMP2
was found to be vital for chondrocyte maturation and to induce a center of endochondral ossification.45–47
However, unlike our data, the center of the implanted ASC pellets did not retain their cartilage phenotype.

A similar stepwise strategy has been used with MSCs in which a chondrogenic pellet was subsequently
cultured in media containing β-glycerophosphate which resulted in a region of bony tissue surrounding a
chondrogenic pellet, similar to the data presented here.37 However, this group found significant type I
collagen present in the chondrogenic area of their organoid, which increased over their 35 days of culture.
As iPSCs tend to show little or no hypertrophic differentiation under chondrogenic conditions, the
chondrogenic area of the organoids in our present study was not positive for type I collagen. Instead, type I
collagen was isolated to the bony exterior regions of the organoids in this study. In addition in our study, we
found many bone-specific genes to be upregulated at the final time point, postosteogenesis, including Alpl,
Bglap, Runx2, Ibsp, Col1a2, and Sp7.
Surprisingly, no differences were detected between the constructs treated with doxycycline compared to
the ones not treated with doxycycline, except for the increase in total DNA content. Although doxycycline
has been shown to inhibit cell growth in many human cell types, it actually has a slight protective effect in
articular cartilage by helping to inhibit cell death and decreasing degradation of cartilage matrix proteins.
This effect likely accounts for the small percentage increase in DNA content in pellets that had doxycycline
exposure.48
Because no differences in osteogenesis between the dox and no dox groups were detected, we were
compelled to further study of the potential of these cells to revert to a pluripotent state. The potential for
dedifferentiation and tumorigenesis of cells derived from iPSCs poses a large hurdle for clinical use of these
cells.29,49 Our study provides evidence that differentiated iPSCs may be resistant to reinduction of
pluripotency while maintained within an ECM. We found that the addition of doxycycline to the media after
chondrogenic differentiation did not cause our iPSC chondrocytes within the 3D cartilaginous matrix to
revert to a pluripotent state, as evidenced by the lack of expression of pluripotency factors, as well as colony
formation and Nanog, Oct4, and SSEA-1 staining. However, when isolated from the matrix, plated in
monolayer, and then treated with doxycycline, we showed the development of colony forming units that
were positive for these pluripotency markers. Previous research has demonstrated that doxycycline is readily
able to diffuse into a cartilage matrix and activate a doxycycline-inducible vector, even in significantly
larger engineered constructs,50,51 suggesting that our findings were not due to a lack of activation of the
vector but rather were likely due to altered behavior of the cells due to interactions with the ECM. In
addition, had doxycycline induction only been able to induce pluripotency in the outer layers of our pellets
due to limited diffusion into the tissue, pluripotent cells would have been detected in the colony pluripotency
assay, which were not.
While a number of previous studies have investigated the influence of matrix properties on the
differentiation of stem cells and iPSCs, there is little known regarding the influence of a 3D ECM on
maintaining cell phenotype and potentially inhibiting pluripotency.52–55 In vivo, tissue-resident stem cells
reside in a 3D niche with mechanical and secreted cues that help them maintain pluripotency.56,57 When the
cells leave the niche, they differentiate, losing their stemness. The cells in our study were encapsulated in an
articular cartilage-like matrix, which is unlikely to have the characteristics of a stem cell niche present to aid
the cells in reverting to a pluripotent state. It is possible that the cells digested from the matrix and plated in
monolayer were primed for reversion, as chondrocytes plated in monolayer tend to dedifferentiate, which
changes their gene and protein expression and may allow for greater plasticity of the cells.56–58 Therefore, it
may have been the presence of a 3D matrix that maintained cell shape, rather than specific proteins in the
matrix, that prevented reversion to a pluripotent state. In addition, while no true stem cell “niche” is present
in articular cartilage, the superficial surface of articular cartilage does contain a population of
chondroprogenitor cells.59 Unlike the chondrocytes in the middle and deep zones of the cartilage, cells in
the superficial zone are flat, similar to cells in monolayer culture. Although it is clear that the chondrogenic
3D matrix prevented de-differentiation of our cells despite externally providing the otherwise necessary and
sufficient factors of pluripotency induction, it is unclear whether a specific matrix protein or the mechanical

forces provided by the matrix inhibited de-differentiation. Further research will be necessary to answer this
question, which could provide additional insights into future clinical utilization of iPSC-derived tissues.
Conclusion

This study provides a strategy for creation of an osteochondral organoid without the need for multiple
cell types, scaffolds, or bioreactors. The creation of this novel iPSC-derived osteochondral organoid
provides a platform for studying normal and pathologic interactions between bone and cartilage at the
osteochondral junction.60 An osteochondral organoid system could provide unique opportunities to study the
process of endochondral ossification and hypertrophy in vitro, as well as basic biologic interactions at the
bone–cartilage interface. These constructs were grown from iPSCs, opening the possibility for in vitro
modeling of the effects of specific genetic variants as risk factors for OA, skeletal dysplasia, or other
musculoskeletal diseases, as well as the possibility for testing drugs in a disease-specific or patient-specific
manner.22,61 Furthermore, while creating these osteochondral organoids, we discovered that the 3D
cartilaginous matrix in which the cells were encapsulated prevented reinduction of pluripotency in the cells,
a critical finding for the future clinical usability of iPSC-derived tissues.
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